Spinal Simplicity’s IntraLink injectable device for disc degradation earned the FDA’s breakthrough device designation, according to an Aug. 14 news release.
IntraLink uses self-polymerizing plant-derived compounds that attach to collagen fibrils in the disc. It mechanically supports the disc to inhibit excess motion and stabilize the spinal joint.
With breakthrough designation IntraLink will get priority FDA review and streamlined, collaborative communication through the premarket review process.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
